paclitaxel,cyclophosphamide and dexamethasone for relapsed or refractory multiple myeloma

Conditions: Relapse/Refractory Multiple Myeloma

Summary: the purpose of this study is to evaluate the efficacy and safety of paclitaxel in combination with cyclophosphamide and dexamethasone in chinese patients with relapsed/refractory multiple myeloma.

treatment for relapsed/refractory multiple myeloma (mm)remains a crucial challenge.the investigators have previously shown that the combination of paclitaxel and cyclophosphamide acts synergistically to induce apoptosis of myeloma cells in vitro. based on these preclinical studies, the investigators initiated a phase ii clinical trial of paclitaxel 175 mg/m(2) iv over 3 h d1 combined with cyclophosphamide 200 mg/m(2) iv over 30-60 min d1,3,5 and dexamethasone 20mg iv over 30-60 min d1-4 in patients with relapsed or refractory mm. this regimen was administered every four weeks for a total of six cycles

Eligibility criteria:
inclusion criteria: * patient has a previous diagnosis of multiple myeloma * patient requires retreatment for multiple myeloma * subject has measurable disease as defined by \> 0.5 g/dl serum monoclonal protein, \>10 mg/dl involved serum free light chain (either kappa or lambda) provided that the serum free light chain ratio is abnormal, \>0.2 g/24 hrs urinary m-protein excretion, and/or measurable plasmacytoma(s) of at least 1cm in greatest dimension as measured by either ct scanning or mri * subject has a karnofsky performance status ≥60% (\>50% if due to bony involvement of myeloma (see appendix iv) * subject has a life expectancy ≥ 3 months * subjects must meet the following laboratory parameters: absolute neutrophil count (anc) ≥750 cells/mm3 (1.0 x 109/l) hemoglobin ≥ 7 g/dl platelet count ≥ 75,000/mm3 (30 x 109/l if extensive bone marrow infiltration) serum sgot/ast \<3.0 x upper limits of normal (uln) serum sgpt/alt \<3.0 x upper limits of normal (uln) serum total bilirubin \<2.0 mg/dl (34 µmol/l) creatinine clearance ≥ 45 cc/min exclusion criteria: * subject has immeasurable mm (no measurable monoclonal protein, free light chains in blood or urine, or measureable plasmacytoma on radiologic scanning) * subject has a prior history of other malignancies unless disease-free for ≥ 5 years, except for basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix or breast, or localized prostate cancer with gleason score \< 7 with stable prostate specific antigen (psa) levels * subject has had myocardial infarction within 6 months prior to enrollment, or nyha (new york hospital association) class iii or iv heart failure (see appendix vi), ejection fraction \< 35%, uncontrolled angina, severe uncontrolled ventricular arrhythmias, electrocardiographic evidence of acute ischemia or active conduction system abnormalities * female subject who is pregnant or lactating * subject has known hiv infection * subject has known active hepatitis b or hepatitis c infection * subject has active viral or bacterial infections or any coexisting medical problem that would significantly increase the risks of this treatment program * subject is unable to reliably take oral medications * subject has known hypersensitivity to dexamethasone,cyclophosphamide,paclitaxel * subject has a history of thromboembolic event within the past 4 weeks prior to enrollment * subject has any clinically significant medical or psychiatric disease or condition that, in the investigator's opinion, may interfere with protocol adherence or a subject's ability to give informed consent

Keywords: paclitaxe,cyclophosphamide,dexamethasone, multiple myeloma